Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001193125-25-331189

Chief R&D Officer acquired 6,250 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Owned after D/I
2025-12-22 Grant or award : show line 1 in the form +6,250 25,221 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-12-22 Grant or award : show line 2 in the form Stock Option +25,000 25,000 D
Loading xslF345X05/ownership.xml…